Suárez-Formigo GM, Saavedra-Hernández D

Language: English
References: 22
Page: 54-56
PDF size: 70.45 Kb.

ABSTRACT

Worldwide, there has been a progressive demographic shift over the past 50 years resulting in a larger proportion of older adults in the general population. Aging itself is a complex biological phenomenon characterized in part by changes in the immune system known as “immunosenescence”, which makes older adults more susceptible to infectious, cardiovascular and autoimmune diseases, as well as cancers. Several strategies have been proposed in an attempt to reverse immunosenescence, including use of hormones, cytokines and thymic factors. A promising drug in the search to restore the thymic microenvironment (which plays an important role in the regulation and maintenance of the immune system) in older adults is Biomodulina T, a Cuban product registered for use in patients with recurrent respiratory infections. The administration of Biomodulina T increases the number of virgin T-lymphocyte, CD4- positive cells that have recently migrated from the thymus gland (recent thymic emigrants) and memory CD8-positive T-lymphocytes, which have characteristics akin to stem cells (stem cell-like memory). Furthermore, the expression of programmed cell death in CD4-Positive T-lymphocytes and CD8-Positive T-lymphocytes decreases, and the proliferative capacity of CD4-Positive T-lymphocytes increases, without changes in the frequency of regulatory T-lymphocytes. These results suggest that the administration of Biomodulina T could be used to restore immunity in older adults and in other immunocompromised individuals, improve response to other immunotherapies in cancer patients, and increase the effi cacy of vaccinations in older adults.

REFERENCES

1. United Nations. Report of the Second World Assembly on Ageing: Madrid, 8-12 April 2002. New York: United Nations; 2002. 72 p.

2. National Health Statistics and Medical Records Division (CU). Anuario Estadistico de Salud 2019 [Internet]. Havana: Ministry of Public Health (CU); 2020 May [cited 2020 May 25]. 206 p. Available at: https://fi les. sld.cu/bvscuba/files/2020/05/Anuario- Electr%c3%b3nico-Espa%c3%b1ol-2019-ed -2020.pdf. Spanish.

3. Cano-Amaro M. El envejecimiento poblacional en Cuba, desde el prisma de la epidemiología social y la ética. Anales Acad Ciencias Cuba. 2016;6(2). Spanish.

4. Fulop T, Larbi A. Biology of aging: paving the way for healthy aging. Exp Gerontol. 2018 Jul;107:1–3.

5. Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, et al. Immunosenescence and infl amm-aging as two sides of the same coin: friends or foes? Front Immunol. 2018 Jan;8:1960.

6. Lang PO, Govind S, Aspinall R. Reversing T cell immunosenescence: why, who, and how. Age (Dordr). 2012 Feb 25;35(3):609–20.

7. Saavedra D, Fuertes SA, Suárez GM, González A, Lorenzo-Luaces P, García B, et al. Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly. Exp Gerontol. 2019 Jun 13;124:110633.

8. Saavedra D, García B, Lage A. T cell subpopulations in healthy elderly and lung cancer patients: insights from Cuban studies. Front Immunol. 2017 Feb 13;8:146.

9. Larbi A, Fulop T. From «truly naive» to «exhausted senescent» T cells: when markers predict functionality. Cytometry Part A. 2014;85(1):25– 35.

10. Sauce D, Appay V. Altered thymic activity in early life: how does it affect the immune system in young adults? Curr Opin Immunol. 2011 Aug;23(4):543–8.

11. Lang PO, Samaras D. Aging adults and seasonal infl uenza: does the vitamin d status (h)arm the body? J Aging Res. 2012;2012:806198.

12. Lang PO, Mendes A, Socquet J, Assir N, Govind S, Aspinall R. Effectiveness of infl uenza vaccine in aging and older adults: comprehensive analysis of the evidence. Clin Interv Aging. 2012;7:55–64.

13. Fulop T, Larbi A, Hirokawa K, Mocchegiani E, Lesourds B, Castle S, et al. Immunosupportive therapies in aging. Clin Interv Aging. 2007 Mar;2(1):33–54.

14. Shammas MA. Telomeres, lifestyle, cancer, and aging. Curr Opin Clin Nutr Metab Care. 2011 Jan;14(1):28–34.

15. CECMED – (Center for State Control of Medications, Equipment and Medical Devices [Internet]. Havana: CECMED; c2019. Registros. Resumen de las características del producto Biomodulina T; [cited 2020 May 25]. 3 p. Available at: https:// www.cecmed.cu/registro/rcp/biomodulinar-t -fraccion-timica. Spanish.

16. Gámez MLA, Lara RRF, Rodríguez MR, González-Quevedo MA, Fernández CR, Marzoa SN. Estudio Fase II de tratamiento de pacientes con esclerosis múltiple exacerbanteremitente con Biomodulina T. Rev Mex Neuroci. 2007;8(1):28–31. Spanish.

17. Christian López LC, Rodríguez Marín RR, Rabassa Pérez J, Santamaría Lafargue M, Romero del Sol JM, González Ross E. Efecto de la biomodulina T 1000 sobre el timo en niños con infecciones recurrentes. Rev Cub Pediatr. 2000 Jan–Mar;72(1):3–9. Spanish.

18. García-Orihuela M, Capdevila V, Suárez-Martínez R, Rodríguez-Rivera L, Castro-González I. Efecto de la Biomodulina T sobre las infecciones respiratorias altas y la polifarmacia del anciano. Rev Haban Cienc Méd. 2014 May– Jun;13(3):425–36. Spanish.

19. Pido-López J, Imami N, Aspinall R. Both age and gender affect thymic output: more recent thymic migrants in females than males as they age. Clin Exp Immunol. 2001 Sep;125(3):409– 13.

20. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011 Oct;17(10):1290–7.

21. Saavedra D, Crombet T. CIMAvax-EGF: a new therapeutic vaccine for advanced non-small cell lung cancer patients. Front Immunol. 2017 Mar 13;8:269.

22. Ferrara R, Mezquita L, Auclin E, Chaput N, Besse B. Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter? Cancer Treat Rev. 2017 Nov;60:60–8.